Higher DNA methylation of ABO gene promoter is associated with acute myocardial infarction in a hospital-based population in Karachi by Yousuf, Farzana Abubakar et al.
eCommons@AKU 
Department of Biological & Biomedical 
Sciences Medical College, Pakistan 
3-2020 
Higher DNA methylation of ABO gene promoter is associated with 
acute myocardial infarction in a hospital-based population in 
Karachi 
Farzana Abubakar Yousuf 
Aga Khan University, farzana.abubakar@aku.edu 
Khawar Kazmi 
National Institute of Cardiovascular Diseases, Karachi, Pakistan 
Junaid Iqbal 
Aga Khan University, junaid.iqbal@aku.edu 
Nikhat Ahmed 
University of Karachi, Karachi, Pakistan 
Mohammad Perwaiz Iqbal 
Aga Khan University, perwaiz.iqbal@aku.edu 
Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_bbs 
 Part of the Life Sciences Commons 
Recommended Citation 
Yousuf, F. A., Kazmi, K., Iqbal, J., Ahmed, N., Iqbal, M. P. (2020). Higher DNA methylation of ABO gene 
promoter is associated with acute myocardial infarction in a hospital-based population in Karachi. 
Pakistan Journal of Medical Sciences, 36(3), 505-510. 
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_bbs/828 
Pak J Med Sci     March - April  2020    Vol. 36   No. 3      www.pjms.org.pk     505
INTRODUCTION
 ABO gene locus encodes for glycosyl 
transferases which modify the terminal 
oligosaccharides of the precursor H antigen, 
thereby making antigen A and antigen B. While 
A and B alleles of ABO gene are enzymatically 
active, the O allele is inactive, and therefore 
cannot modify precursor H antigen leading to 
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ABSTRACT
Objective: To find out if there is any relationship of methylation status of ABO gene promoter with 
the risk of acute myocardial infarction (AMI) in a hospital-based Pakistani population in Karachi, 
Pakistan.
Methods: A case control study comprising of 39 adult AMI patients (both males and females; age range 
30-70 years) and 39 normal healthy controls (both males and females and similar age range) nested in a 
large study (to see the relationship of ABO genotypes with AMI) was designed to investigate the methylation 
status of ABO gene promoter and its association with AMI. The study was carried out at the Aga Khan 
University, Karachi during July 2018 to June 2019. DNA isolated from samples of AMI patients and normal 
healthy controls were converted into bisulphite DNA using a kit method. Methylation specific polymerase 
chain reaction was carried out to determine the methylation status of ABO gene promoter in both cases and 
controls. Logistic regression was used to find out any association between increased methylation status of 
ABO gene promoter and risk of AMI.
Results: A significantly higher percentage of DNA methylation of the ABO gene promoter was observed 
in AMI patients as compared to normal healthy controls (82.1% vs. 35.9%; p value <0.001). This higher 
methylation status of ABO gene promoter was associated with AMI and the odds of AMI in this population 
were more than 6-fold in subjects with methylated gene promoter compared to those with unmethylated 
gene promoter after adjusting with age and waist circumference [AOR (95% CI) = 6.27 (1.76-22.3); p value 
= 0.005].
Conclusion: The ABO gene promoter’s hypermethylation appears to be increasing the risk of AMI in a 
hospital-based Pakistani population in Karachi, Pakistan.
KEYWORDS: ABO gene promoter, Acute myocardial infarction, Coronary artery disease, DNA methylation, 
Pakistani population.
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O antigen.1 Therefore, expression of ABO gene 
locus is associated with the expression of ABO 
phenotypes in individuals.
 A systematic review by Chen et al., 2016 has 
shown an association of blood group A and non 
O blood groups with increased risk of coronary 
artery disease (CAD).2 A recent report from China 
indicated that blood group A was an independent 
risk factor for severity of CAD.3 These reports 
show that expression of ABO gene has an indirect 
relationship with the development of CAD.
 DNA methylation is an epigenetic modulation 
mechanism in which cytosine bases of the 
eukaryotic DNA immediately followed by 
guanine residues i.e. CpG (cytosine-phosphate-
guanine) islands present in the promoter region 
are converted to 5 methylcytosine with the 
help of the enzyme DNA methyltransferases.4 
ABO gene promoter region has a CpG island 
whose methylation status correlated with gene 
expression in the cell lines.5 A study by Zaina et al. 
showed an association of differentially methylated 
CpG islands with the onset of atherosclerosis 
and endothelial dysfunction.6 Since ABO gene 
locus has also been identified to be associated 
with myocardial infarction in patients with CAD 
symptoms,7 it is imperative to investigate the 
methylation status of ABO gene promoter to see 
whether it has a relationship with acute myocardial 
infarction (AMI) in a Pakistani population which 
has one of the highest known rates of CAD in the 
world.8 While a few studies have been carried 
out to study the effect of epigenetic factors on 
some of the clinical diseases such as metabolic 
diseases and psychiatric illnesses among South 
Asian immigrants in the West, hardly any 
investigation on the role of DNA methylation 
and the development of premature CAD has 
been conducted on South Asians.9,10 Therefore the 
objective of the study was to find out if there is any 
relationship of methylation status of ABO gene 
promoter with the risk of AMI in a hospital-based 
Pakistani population.
METHODS
Study design, sampling and sample size: This 
is a case control study nested in a large cohort 
study which had the purpose to investigate the 
relationship of ABO genotypes with AMI in a 
Pakistani population in Karachi. For the large 
study, the AMI patients’ samples (both males 
and females with the age range from 30-70 years 
and having a confirmed diagnosis of AMI) had 
been obtained from the National Institute of 
Cardiovascular Disease (NICVD), Karachi with 
informed consent, while normal healthy subjects 
(both males and females with same age range from 
30-70 years and not suffering from any chronic 
disease including CAD) were recruited from the 
personnel of the Aga Khan University (AKU) 
and NICVD. The study had the approval of the 
Ethics Review Committees (ERC) (Ref#: 3048-BBS-
ERC-14 dated on July 17, 2018) of the AKU and 
NICVD (Ref#: ERC-10/2015 dated on May 30, 
2015). The nested current case control study was 
carried out at the AKU during the period July 
2018 to June 2019. DNA samples isolated from 
AMI patients (n=39) and normal healthy controls 
(n=39) were randomly selected from the samples 
collected for the large study.
Sample Size: In a case control design with power 
of at least 80% and level of significance of 5%, a 
sample size of 39 in each patients group (cases) 
and healthy subjects group (control) was worked 
out when exposure ranged from 10% - 45% with an 
anticipated odds ratio of four or more.11 Therefore, 
39 DNA samples of AMI patients and 39 DNA 
samples of healthy controls were employed for 
methylation profiling of ABO gene promoter to 
investigate any association of methylation status 
of promoter and risk of AMI in this population. 
Demographic and clinical characteristics of patients 
and healthy controls such as gender, age, body 
mass index (BMI), waist circumference (WC) and 
blood pressure were obtained from the record of 
the study participants.
DNA Extraction and Bisulfite Conversion: Salting 
out method was used for isolation of genomic 
DNA from white blood cells of AMI patients and 
normal healthy control subjects using standard 
protocol.12 The amount of DNA was quantitated 
at 260 nm and the purity was checked by taking 
the optical density (OD) at the ratio 260/280. The 
DNA methylation experiments were then carried 
out on the purified DNA.
 The MethylEasy™ Xceed Rapid DNA Bisulphite 
Modification Kit (Genetic signatures company, 
Australia) was used for the conversion of DNA 
into bisulphite DNA following manufacturer’s 
instruction. In this process, cytosine is converted 
to uracil but does not convert 5-methylcytosine 
(5-mc) bases as they are unreactive. The genomic 
DNA (5 µg) obtained from both the study groups 
(cases and controls) along with a positive control 
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1 (untreated DNA, as provided in the kit) was 
used. The integrity of the DNA samples after 
bisulphite conversion was checked by nested 
PCR using primers 3A (first round) and 3B 
(second round) and a control sample 2 (which 
contained bisulphite treated DNA) as positive 
control (all provided in the kit). The product size 
of the amplicon was 240bp that was analyzed on 
a 2% agarose gel. Now the bisulfite treated DNA 
samples were ready to be used in methylation 
specific PCR (MSP) for the profiling of ABO 
gene promoter.
Methylation specific PCR (MSP): The MSP 
technique detects the average DNA methylation 
status of any gene. The targeted methylated region 
of the human ABO gene was amplified by using 
methylation specific primers and unmethylated 
specific primers as described by Kominato 
et al.5 The unmethylated primer sequences 
for forward and reverse primers were (U1) 
5’GGATAGGGTTTTAAGGTATTAGGGTTATG3’ 
and (U2) 5’CCACATCTAATCTCAACCTCCA3’, 
respectively. The steps for the amplifications 
of unmethylated PCR reaction were: initial 
denaturation for nine minutes at 95°C (one 
cycle only), then 38 repeated cycles of one 
minute at 94°C, one minute at 60°C, two minute 
at 72°C and extension at 72°C for 10 minutes. 
The methylation specific primer sequences 
of forward and reverse primers were M1 
5 ’TTAAGGTATTAGGGTTACGAGGGGC3’ 
and M2 5’CGACCATAACTCCGCGTCT3’, 
respectively. The amplification of the methylated 
PCR reaction was performed as described in the 
following: Initial denaturation at 95°C for 9 minutes 
(one cycle only) and then 38 repeated cycles at 94°C 
for one minute, 67°C 1 minute, 72°C two minutes 
and extension at 72°C for 10 minutes. The total 
reaction volume was 50 µl containing two units of 
AmpliTaq Gold® 360 DNA polymerase (Applied 
Biosystems®) and 20 ng of bisulfite converted 
DNA. The 2% agarose gel containing ethidium 
bromide was used to visualize the amplified PCR 
products which had a size of 280bp. 
Statistical Analysis: Demographic and clinical 
data were analyzed using Statistical Package for 
Social Sciences (SPSS) software version 19 for 
Windows (Apache Software Foundation, USA) 
by IBM. The mean ± SD values of continuous 
variables (age, BMI, WC, blood pressure) between 
cases and controls were analyzed by Independent 
samples t test. The frequencies of methylated 
and unmethylated ABO gene promoter among 
AMI patients and normal healthy controls were 
compared using Chi-Square test. In order to study 
the association of methylation status of ABO gene 
promoter, binary logistic regression was used. 
A p value < 0.05 was considered statistically 
significant.
RESULTS
 Fig.1 shows the gel picture of a typical 
methylation specific PCR (MSP). Being a sensitive 
technique it enables the examination of all CpG 
sites. Moreover, it permits simultaneous detection 
of both methylated and unmethylated products in 
a single DNA sample.13
 The baseline demographic and clinical 
characteristics of both AMI patients and normal 
healthy subjects serving as controls have been 
compared and indicate statistically significant 
differences between the two groups in age and 
waist circumference (p value < 0.001 and p 
value = 0.005, respectively), while no significant 
differences were observed with respect to gender, 
BMI, systolic blood pressure and diastolic blood 
pressure (Table-I). Frequency distribution of 
methylated and unmethylated ABO gene promoter 
in Pakistani AMI patients and normal healthy 
Hypermethylation of ABO gene promoter and AMI
Fig.1: Methylation specific PCR (MSP) amplified 
products using methylated primer set marked as 
M and unmethylated primer ser marked as U 
for ABO gene promoter in AMI patients and 
normal and normal healthy controls.
Lane 1= 100bp Marker, Lane 2-5= Normal healthy 
control samples (band in only unmethylated), Lane 6-9= 
AMI patients samples (bands in both unmethylated 
and methylated), M = Methylated PCR product, U = 
Unmethylated PCR product.
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controls has been shown Table-II. Significantly 
higher proportion of DNA methylation has been 
found in the ABO gene promoter of AMI patients 
as compared to healthy controls (82.1% vs. 35.9%; 
p value < 0.001). Binary logistic regression analysis 
revealed an association of higher methylation 
status of ABO gene promoter with AMI and the 
odds of AMI were 6.27 folds higher in methylated 
ABO gene promoter subjects compared to subjects 
with unmethylated ABO gene promoter, when 
adjusted for age and waist circumference [AOR 
(95% CI) = 6.27 (1.76-22.3); p value 0.005, Table-III]. 
As epigenetic changes, in general, increase with 
age,14 the regression model to study association 
of promoter with AMI was adjusted for age. 
Moreover, waist circumference has been reported 
to be a better predictor of CAD compared to BMI 
in Pakistani population,15 therefore, the logistic 
regression model was also adjusted for waist 
circumference. When the ABO gene promoter 
was hypermethylated, the odds of having AMI 
increased more than 6 folds in this population.
DISCUSSION
 Coronary heart disease (CHD) is the major cause 
of death in Pakistan.8 Another study from Pakistan 
indicated that prevalence of CAD was more than 
6% in people of the age greater than 30 years.16 
Since non-O group individuals predominate in this 
population, it is conceivable that the risk of CAD 
would be high in this population. The underlying 
mechanism of association of non-O blood group 
antigens with CAD has not been defined clearly, 
however there are reports which show that 
non-O group subjects have 25% higher levels of 
factor VIII-vWF complex compared to group O 
individuals and vWF (von Willibrand factor) is 
known to have a role in thrombosis by mediating 
the adhesion of platelets to vascular wall and 
promoting their aggregation, thereby increasing 
the risk of CAD.17 Moreover, expression of ABO 
gene locus is also associated with plasma levels of 
lipids. For example, blood group A subjects have 
been found to have higher levels of total cholesterol 
and low-density lipoprotein cholesterol.18 Another 
possible mechanism for the association of blood 
groups A and non-O could be increased expression 
of inflammatory molecules such as tumor necrosis 
factor alpha which is known to mediate endothelial 
cell activation by increasing the expression of 
various adhesion molecules.17 All these reports 
show the possible mechanism linking ABO gene 
locus with the risk of CAD. However, most of these 
lines of evidence deal with traditional risk factors 
of CHD.  Besides these traditional risk factors, 
epigenetic factors could also be playing some role 
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Table-I: Baseline and clinical characteristics of normal 
healthy controls and patients with acute myocardial 
infarction (AMI) in a Pakistani population.
Characteristics Normal healthy  AMI patients p value*
 controls (n =39) (n =39) n (%)
 n (%) 
Gender
  Males 32(82.1) 33(84.6) 0.99
  Females 7 (17.9) 6 (15.4)
 Mean ± SD Mean ± SD
Age (years) 42.13 ± 7.68 53.87±8.87 < 0.001
BMI (kg/m2) 25.1 ± 3.8 25.8 ± 3.8 0.473
WC (cm) 90.3 ± 8.7 96.4 ± 9.8 0.005
SBP (mm of Hg) 119 ± 14 120 ± 14 0.75
DBP (mm of Hg) 78 ± 7 78 ± 12 0.95
BMI: body mass index, WC: waist circumference,
SBP: systolic blood pressure, 
DBP: diastolic blood pressure.
* p value represents the comparison of percentages in two 
groups using chi-square, while means were compared 
using Independent samples t test. A p value < 0.05 was 
considered as significant.
Table-II. Frequency distribution of methylated 
and unmethylated status of ABO gene 
promoter in a Pakistani population.
 Status of ABO gene promoter
Subjects Unmethylated  Methylated P value*
 (%) (%)
Cases (n=39) 7 (17.9) 32 (82.1) < 0.001
Controls (n=39) 25 (64.1) 14 (35.9)
*p value was determined using chi-square test.
p value < 0.05 was considered as significant.
Table-III: Association of ABO gene promoter’s methylation with the 
risk of AMI in a Pakistani population using binary logistic regression.
Status of ABO gene promoter Crude OR (95% CI) p value Adjusted OR (AOR)1 (95% CI) p value
Unmethylated 1.0  1.0 
Methylated 8.1 (2.86-23.26) <0.001 6.27 (1.76-22.3) 0.005
1Adjusted for age and waist circumference.
Hypermethylation of ABO gene promoter and AMI
for the high prevalence of this disease in Pakistan. 
Epigenetic refers to changes in gene expression 
without alteration in DNA sequence in response 
to environmental factors such as smoking, diet and 
lack of physical activity.19 DNA methylation on the 
CpG islands in the gene promoter region is one of 
the most studied epigenetic modifications.20 It has 
been shown to regulate the expression of genes 
associated with cardiovascular disease (CVD) risk 
factors including atherosclerosis, inflammation, 
hypertension and diabetes mellitus.21,22 Recent 
studies have shown ABO gene locus as a 
susceptibility locus for CAD, MI and other diseases, 
and the environmental factors and epigenetic 
signatures contribute in the process of development 
of CAD.23 There is evidence of association of non-O 
blood groups to the risk of developing CAD.2 
However, in certain populations, there was no 
significant association of non-O group with the risk 
of CAD.24 This indicates that this association could 
vary from one population to another.
 There has been no report in the literature 
describing the relationship of expression of ABO 
gene promoter with the risk of CAD in South 
Asian population. Kominato et al. had described 
that hypermethylation of ABO gene promoter 
caused silencing of the gene in stomach carcinoma 
cell line.5 Later Bianco-Miotto et al., reported 
that hypermethylation of ABO promoter was 
associated with the loss of ABO allelic expression 
in patients with leukemia.25 Therefore, the current 
study is unique in reporting the association of 
higher methylation of ABO gene promoter to 
the risk of AMI in a Pakistani population. The 
mechanism by which hypermethylation of ABO 
gene promoter could be related to the risk of AMI 
is unclear. However, it can be conjectured that 
similar to the allelic loss observed in patients with 
hematological malignancies,25 there could be a 
loss of ABH antigens in patients with AMI with 
associated complications such as thrombosis and 
altered endothelial function.26 Duygu et al., have 
reported association of DNA methylation with 
arrhythmias and heart failure.27 Though they 
have not described the mechanism involved, but 
their findings do indicate a relationship of gene 
silencing with heart disease.
Limitations of the study: Though the sample size 
was modest, however, the study had adequate 
power to investigate the relationship between 
hypermethylation of promoter and risk of 
AMI. Furthermore, the design of the study was 
cross sectional; therefore, it could only provide 
information about association or relationship 
between hypermethylation of ABO gene promoter 
and risk of AMI. No cause-effect relationship could 
be inferred from such a design. In order to obtain 
information whether hypermethylation could 
be the cause of AMI, some kind of longitudinal 
studies would be required. Another limitation of 
the current study is the lack of detailed information 
about various drugs and medications used by the 
patients and healthy controls because certain drugs 
have been shown to alter the epigenetic profiling to 
a favorable status.28 Thus, large studies involving 
measurements at different time intervals along 
with complete information about medicines used, 
their diet, physical activity and comorbids would 
be required to obtain some conclusive evidence 
regarding the role of epigenetics in causing CAD in 
Pakistani population.
CONCLUSION
 There is an association between higher 
methylation of ABO gene promoter and the risk 
of AMI in a hospital-based Pakistani population. 
Since the epigenetic changes are reversible, they 
offer exciting opportunities for better treatment and 
management of chronic diseases such as CVD.
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